TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the following corporate updates;1. FSD Pharma Inc. (the "Company")199 Bay Street. FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today reported its financial and operational results for the third quarter of fiscal 2018, ended September 30, 2018. FSD Pharma Inc. is a publicly-traded holding company, since May 2018. TORONTO, January 20, 2022 -- ( BUSINESS WIRE )--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (" FSD Pharma " or the " Company "), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the launch of its newly designed website. About FSD Pharma . Financial and corporate highlights include: Completion of financings for gross … FSD Pharma adds industry leaders Jason Sawyer and Dr. Ravinder … FSD BioSciences, Inc. (“ FSD BioSciences ”), a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“ PEA ”) or FSD-PEA (formerly called FSD-201). Stockhouse.com uses cookies on this site. FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. Donal Carroll, Chief Financial Officer, FSD Pharma Inc. Dcarroll@fsdpharma.com. Interim Chief Executive Officer at FSD Pharma. (2020-05-14 | CSE:HUGE) FSD Pharma Reports First Quarter 2020 Financial Results. FSD Pharma Inc. is a publicly-traded holding company, since May 2018. 4. The foregoing statements expressly qualify any Forward-Looking Information contained herein. The foregoing statements expressly qualify any Forward-Looking Information contained herein. Sandy Huard, Head of Communications, FSD Pharma Inc. sandy@fsdpharma.com (647) 864-7969 Zeeshan Saeed, President, FSD Pharma Inc. zeeshan@fsdpharma.com. For financial reporting, their fiscal year ends on December 31st. Donal Carroll joined FSD Pharma as interim Chief Financial Officer in 2018 and was appointed to the position on a permanent basis in December 2019. TORONTO — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today it has retained the services of Hybrid Financial Ltd. (“Hybrid”), North Equities Corp. (the “North Equities“), Looking Glass … FSD Pharma has been expanding its team aggressively at all levels to synergize its operations. FSD Pharma Inc. is a publicly-traded holding company. ... LHA Investor Relations Sanjay M. Hurry shurry@lhai.com (212) 838-3777 Source: … TORONTO — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce the completion of … TORONTO, June 9, 2020 /CNW/ - FSD Pharma Inc. Investor Relations IR@fsdpharma.com. These filings are available for review under the Company's SEDAR profile at www.sedar.com and the Company’s EDGAR profile at www.sec.gov. FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. 1. The corporate information is based on information that is publicly available. Cookies are used to offer you a better browsing experience and to analyze our traffic. Based in the United Kingdom, Jessica manages relationships in the UK and Europe, as well as providing hands-on accounting management to several Grove clients. TORONTO (July 31, 2020) FSD Pharma Inc. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. The information in this Investmentpitch Media Ltd video is for the viewers information only. FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE: HUGE) (OTC: FSDDF) reported its financial and operational results for the second quarter of fiscal 2018, ended June 30th, 2018. The Company recently announced a US $20M at-the-market offering, the closing of a US $10M registered direct offering to institutional investors, and the voluntary surrender to Health Canada of its medicinal cannabis grow license and the shutdown of subsidiary FV Pharma, Inc. About FSD Pharma Elon Musk meldt dat hij niet langer zijn aandelen in Tesla wil gebruiken voor het financieren van een lening voor de overname van Twitter. Investor Relations: Email: ir@fsdpharma.com, info@fsdpharma.com Website: www.fsdpharma.com. FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over … Toronto, June 27, 2022 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the results of its annual general meeting of shareholders (“AGM”), held online and in virtual-only format on June 23, 2022. FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201, by down-regulating the cytokines to effectuate an anti-inflammatory response. FSD Pharma Issues Corporate Updates. FSD Pharma returns to treasury 1,524,700 shares as of 31 March through its buyback program. FSD Pharma Private Companies Public FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and … ... FSD Pharma, Inc., sandy@fsdpharma.com, (647) 864-7969; Investor Relations, IR@fsdpharma.com, www.fsdpharma.com, Or LHA Investor Relations, Sanjay M. … Source: FSD Pharma Inc. ... Investor Relations, IR@fsdpharma.com, www.fsdpharma.com Or LHA Investor Relations, Sanjay M. Hurry, shurry@lhai.com, (212) … Lucid Adds Potential for Neurodegenerative Disease Treatments and Mental Health in a Novel Way. FSD Pharma Inc. is pleased to announce that Executive Co-Chairman and CEO Dr. FSD Pharma is a ... LHA Investor Relations Sanjay M. Hurry shurry@lhai.com (212) 838-3777 Source: FSD Pharma, Inc. Jessica has worked for Grove for 12 years, serving in the areas of finance, administration and investor relations. This Group communication should not be used as a basis... FSD Pharma HUGE Investors Group TORONTO--(BUSINESS WIRE)--Feb 25, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it has entered into a firm agreement in connection with the sale of its former cannabis processing … Investor Relations Business Wire FSD Pharma Issues Corporate Updates ... Apr 6, 2022 12:30 PM UTC. Password requirements: 6 to 30 characters long; ASCII characters only (characters found on a standard US keyboard); must contain at least 4 different symbols; Pressemitteilung von EASYFITNESS Franchise GmbH Erneuter Bundesrekord mit EMS-Konzept von EASYFITNESS: Zweites EMS-Studio eröffnet mit 164 Mitgliedern veröffentlicht auf openPR Toronto, Ontario. Kotra serves as CEO of FSD Pharma’s wholly owned subsidiary, Lucid Psycheceuticals With experienced leadership, a diverse pipeline of clinical assets accompanied by exclusive licensing rights, and therapies advancing to treat pervasive medical conditions, like inflammation, MS and Depression, FSD Pharma is on a strong trajectory for growth TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update.The filing is available on SEDAR. FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. Suite 4000. The new site conveys the Company’s emerging position within the … Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as the Company's financial advisor for the offering. At present, the record date for the Annual Meeting is April 14, 2021, the Annual Meeting date is May 14, 2021, and the Company's proxy materials are expected to be mailed to shareholders on or before April 23, 2021. Article content. Mr. Durkacz has served as a director and the Executive Vice-President of First Republic Capital Corporation since 20 14. FSD Pharma team includes 2 Julia Levy Award recipients, a distinguished award that has only been awarded to 8 recipients since its inception in 2005 (no other company can make this claim) Strong Cash Position Cash significant for 3+ years of operations (including 3 planned clinical trials) No dilution on horizon for shareholders 3. FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, ultramicronized-palmitoylethanolamide ("FSD201"), by down-regulating the cytokines to effectuate an anti-inflammatory response. The Company does not undertake to update any forward-looking statements, except to the extent required by applicable securities laws. Media Relations: KCSA Strategic Communications Email: FSDPharma@KCSA.com For further information: Sandy Huard, Head of Communications, FSD Pharma Inc. sandy@fsdpharma.com (647) 864-7969 Zeeshan Saeed, President and Founder, FSD Pharma Inc. zeeshan@fsdpharma.com (416) 854-8884 Investor Relations IR@fsdpharma.com www.fsdpharma.com Or LHA Investor Relations Miriam Weber Miller MMiller@lhai.com (212) 838-3777 Source: FSD Pharma Inc. TORONTO, July 27, 2021--FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the "Company" or "FSD") announced today that the board of directors had terminated the employment of the Company’s Chief Executive Officer, Dr. Raza Bokhari for cause. $300+ A Day get it here: https://bit Flexible Spending Accounts (FSA) Plan Transaction History Remove Junk The strength of the app Our public relations firm has represented some of the most inspiring and pioneering clients in the areas of social justice and advocacy, human rights, business and … FSD Pharma Inc. Released October 17, 2019 About FSD Pharma . August 25, 2021. FSD Pharma is appealing both aspects of the decision and has asked the Court to hear the appeal on an expedited basis. Disclaimer. Disclaimer. Announces US$10 Million Registered Direct Offering . A news release (the "News Release") describing the material change was issued by the Company through the facilities of Business … Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more Sandy Huard, Head of Communications, FSD Pharma, Inc. sandy@fsdpharma.com (647) 864-7969 Zeeshan Saeed, President & Founder, FSD Pharma, Inc. Zeeshan@fsdpharma.com (416) 854-8884 Investor Relations IR@fsdpharma.com www.fsdpharma.com Or LHA Investor Relations Sanjay M. Hurry shurry@lhai.com (212) 838-3777 TORONTO, January 20, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the launch of its newly designed website. For investor relations email IR@FSDPharma.com. Prior to co-founding the Company, Mr. Durkacz was President of Capital Ideas Investor Relations. Investor Relations IR@fsdpharma.com FSD Pharma has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format. FSD Pharma adds industry leaders Jason Sawyer and Dr. Ravinder Kumar to its Advisory Board. Jason Sawyer brings 29 years of alternative investment and business experience to FSD’s drug development efforts. FSD Pharma is appealing both aspects of the decision and has asked the Court to hear the appeal on an expedited basis. Sandy Huard, Head of Communications, FSD Pharma Inc. sandy@fsdpharma.com (647) 864-7969 Zeeshan Saeed, President, FSD Pharma Inc. zeeshan@fsdpharma.com. Released February 11, 2021 FORM 51-102F3. TORONTO, December 03, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright 2nd Annual Virtual … Telephone TORONTO, April 06, 2022--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the following corporate updates;. FSD Pharma Inc is primarely in the business of pharmaceutical preparations. Article content. FSD Pharma adds industry leaders Jason Sawyer and Dr. … Edit GOLD; $1871.85 UP $21.40 SILVER: $21.93 UP $.13 ACCESS MARKET: GOLD $1871.00 SILVER: $21.88 Bitcoin morning price: $29941 DOWN 168 Bitcoin: afternoon price: $28977 DOWN 1032 GOLD; $1847.60 Platinum … Item 2 Date of Material Change. FSD Pharma Inc. (NASDAQ: HUGE) () (FRA: 0K9A) (“FSD Pharma” or the “Company”) announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, accompanied by FSD Pharma Biosciences leadership, will be participating in the 22 nd Annual BIO CEO & Investor conference, including presenting a company overview at 9:45 … Read about FSD Pharma Inc Ordinary Shares - Class B (Sub Voting) (HUGE:XNAS) stock and today's latest news and financial updates. TORONTO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, … M5L 1A9. Stockhouse.com uses cookies on this site. shubs-subdomains.txt - Free ebook download as Text File (.txt), PDF File (.pdf) or read book online for free. Investor Relations: Email: ir@fsdpharma.com, info@fsdpharma.com Website: www.fsdpharma.com By continuing to use our service, you agree to our use of cookies. FSD Pharma adopts the RSU program and issues RSUs in Lieu of options held by Directors and Senior Management. Zeeshan Saeed, President and Founder, FSD Pharma Inc. Email: zeeshan@fsdpharma.com Telephone: (416) 854-8884 Investor Relations Email: IR@fsdpharma.com Website: www.fsdpharma.com Or LHA Investor Relations Miriam Weber Miller, +1 212-838-3777 MMiller@lhai.com Media Relations Ned Berkowitz Email: … TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the "Company") today announced the appointments of three key executives: Donal Carroll, Chief Financial Officer.Mr. FSD Pharma has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format. Toronto, March 3 1, 2022 - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the filing of its Annual Report on Form 20-F for the year ended December 31, 2021, audited financial results for the fourth … Advisor Insights; Personal Finance; Market Volatility; Retirement Planning; Start Investing; Save for College; Best Investments; See All TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the "Company") announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, will present an overview of the Company at the Investor Summit conference at 2:35 p.m. FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD Pharma Inc, (CSE:HUGE), a licensed producer under the Cannabis Act, today provided a corporate update on operations, strategy and leadership changes. FSD Pharma Inc. Sandy Huard, Head of Communications, FSD Pharma, Inc. sandy@fsdpharma.com (647) 864-7969 Investor Relations IR@fsdpharma.com www.fsdpharma.com Or FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by FSD Pharma Inc.. ... Investor Relations. FSD Pharma Inc. BEST Money Making Cash App for iOS/Android (NO SURVERYS!) At present, the record date for the Annual Meeting is April 14, 2021, the Annual Meeting date is May 14, 2021, and the Company’s proxy materials are expected to be mailed to shareholders on or before April 23, 2021. Announces Closing of US $10 Million Registered Direct Offering to Institutional Investors August 6, 2020 GMT TORONTO, ON / ACCESSWIRE / August 6, 2020 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE.CN) ("FSD Pharma" or the "Company") announces the closing of a previously announced agreement with investors for the purchase … About FSD Pharma. FSD PHARMA HUGE INVESTORS GROUP ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. TORONTO, ON / ACCESSWIRE / August 6, 2020 / FSD Pharma Inc. Mutual Fund Screener Mr. Durkacz is the “D” in FSD. The company adds the following employees to … FSD Pharma Reports First Quarter 2020 Financial Results - read this article along with other careers information, tips and advice on BioSpace. FSD Pharma Inc. (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today that Dr. Raza Bokhari, Co-Chairman and Chief Executive Officer of FSD Pharma will participate in the Arcview Investor Forum being held April 23-25, 2019, in Vancouver.The event will feature leading public and private companies and thought leaders … MATERIAL CHANGE REPORT. FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over … FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ... will be available on-demand for conference attendees starting at 7:00 a.m. Investor Relations IR@fsdpharma.com Item 1 Name and Address of Company. Carroll previously served as interim CFO; Sandra Lottes, Pharm D, Vice President & Head of Clinical Research of FSD … An application seeking a Court order was filed by FSD on July 21, 2021, with a hearing taking place on December 20, 2021. For investor relations in Canada email IR@FSDPharma.com and in the United States, contact Stephen Kilmer at SKilmer@FSDpharma.com. FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, ultramicronized-palmitoylethanolamide (“FSD201”), by down-regulating the cytokines to effectuate an anti-inflammatory response. ET and accessible to view on the investor relations section of FSD’s website at https: ... members of FSD Pharma’s management team will be available for one-on-one investor meetings during the conference.